SS-31
Mitochondria-targeted peptide that protects cellular energy production
Clinical Research Score: 5/5 — Its drug form elamipretide is FDA-approved as Forzinity (accelerated approval, September 2025) — the first treatment for Barth syndrome and the first mitochondria-targeted therapeutic.
Categories: Anti-Aging / Longevity, Performance & Energy
What is SS-31?
SS-31 goes straight to the source of cellular energy — your mitochondria. These are the power plants inside every cell, and when they decline (as they do with age), everything suffers: energy drops, recovery slows, exercise capacity diminishes, and you feel fundamentally older.
People report that SS-31 restores something that's hard to describe — a baseline vitality that had quietly faded over the years. Exercise feels easier. Recovery is faster. Fatigue lifts in a way that sleep and caffeine never quite achieved. It's not a stimulant rush — it's a genuine improvement in how efficiently your body produces energy at the cellular level.
SS-31 is particularly exciting because it addresses one of the core mechanisms of aging. Mitochondrial dysfunction is now recognized as a primary driver of age-related decline, and SS-31 directly protects and optimizes these critical cellular structures. It's a foundational compound in many longevity protocols for this reason.
How SS-31 works
SS-31 is uniquely designed to penetrate directly into the inner mitochondrial membrane — the exact location where your cells produce energy. There, it stabilizes cardiolipin, a critical molecule that keeps the energy-production machinery running smoothly. It reduces the production of damaging free radicals (reactive oxygen species) that accumulate with age and damage mitochondria from the inside. The net result is mitochondria that produce energy more efficiently, generate less cellular waste, and last longer.
Scientific overview
SS-31 (Elamipretide) is a cell-permeable, mitochondria-targeted tetrapeptide that selectively concentrates in the inner mitochondrial membrane. It stabilizes cardiolipin, reduces reactive oxygen species (ROS) production, and optimizes electron transport chain function. It has shown promise in age-related mitochondrial dysfunction and various degenerative conditions.
Dosing
- Starting dose: 5 mg per day
- Common dosage range: 5-50 mg per day
- Administration: Subcutaneous
- Half-life: ~4 hours
- Frequency: 1x daily